Women across the nation have connected online over their unexpected pregnancies, known as "Ozempic babies," while using GLP-1 ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company’s total revenues. Both drugs enjoy increasing market share ...

Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first ...